Table 4. Recent published studies of incidental ICC or cHCC-CC after liver transplantation for hepatocellular carcinoma.
| Author | Country; year | Number (%) | ICC/cHCC-CC | Milan met (%) | 1-year, 3-year, 5-year survival (%) | Misdiagnosis as HCC | Explant size (cm); number | Alpha-fetoprotein (ng/mL) | Recurrence (%) |
|---|---|---|---|---|---|---|---|---|---|
| Our study | Tokyo; 2016 | 3 (2.0) | 1/2 | 100 | 100, 100, 100 | 2 (67%) | 1.8; 1 [1–8] | 7.6 [7–17] | 0 |
| Sapisochin et al. (34) | Spain; 2014 | 42 (2.8) | 27/15 | 100 | ICC: 78, 66, 51; cHCC-CC: 93, 78, 78 | 42 (100%) | 2.9; 1 [1–10] | 8 [1–295] | 21 |
| Facciuto et al. (31) | USA; 2015 | 32* (1.0) | 16/16 | NA | 71, NA, 57 | 28 (88%) | 2.5; 1 [1–5] | NA | 38 |
| Takahashi et al. (32) | USA; 2015 | 13 (1.1) | 9/4 | 100 | 60, 22***, NA | 8 (62%) | 1.9; 2.1 | NA | 54 |
| Serra et al. (38) | Italy; 2016 | 5** (0.8) | 1/4 | 0 | Mean 28 months | NA | 2.5; NA | NA | 43 |
| Ito et al. (37) | Kyushu; 2015 | 8 (4.5) | cHCC-CC 5 | 75 | 88, 73, 73 | NA | 2.6; NA | 19.7 | 14 (3-year) |
| Maganty et al. (35) | USA; 2010 | 3 (NA) | cHCC-CC 3 | 66 | 67, 33, 33 | 2 (67%) | 2; 1 (1–multi) | 8.6 | 66 |
| Chan et al. (36) | Hong Kong (China); 2007 | 3 (7.0) | cHCC-CC 3 | 66 | 67, 67, 67 | 2 (67%) | 5.8; 1 | NA | 33 |
*, including four biopsy-proven intrahepatic cholangiocarcinoma; **, including one primary sclerosing cholangitis; ***, only moderately differentiated group (68%). cHCC-CC, combined hepatocellular carcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; NA, not available.